The Intratumoral Heterogeneity Reflects the Intertumoral Subtypes of Glioblastoma Multiforme: A Regional Immunohistochemistry Analysis.
glioblastoma
histological architecture
histological subtypes
intertumoral heterogeneity
intratumoral heterogeneity
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
10
2019
accepted:
19
03
2020
entrez:
12
5
2020
pubmed:
12
5
2020
medline:
12
5
2020
Statut:
epublish
Résumé
Glioblastoma multiforme (GBM) is the most frequent and aggressive primary brain tumor in adults. Despite extensive therapy the prognosis for GBM patients remains poor and the extraordinary therapy resistance has been attributed to intertumoral heterogeneity of glioblastoma. Different prognostic relevant GBM tumor subtypes have been identified based on their molecular profile. This approach, however, neglects the heterogeneity within individual tumors, that is, the intratumoral heterogeneity. Here, we detected the regional immunoreactivity by immunohistochemistry and immunofluorescence using nine different markers on resected GBM specimens (IDH wildtype, WHO grade IV). We found repetitive expression profiles, that could be classified into clusters. These clusters could then be assigned to five pathophysiologically relevant groups that reflect the previously described subclasses of GBM, including mesenchymal, classical, and proneural subtype. Our data indicate the presence of tumor differentiations and tumor subclasses that occur within individual tumors, and might therefore contribute to develop adapted, individual-based therapies.
Identifiants
pubmed: 32391260
doi: 10.3389/fonc.2020.00494
pmc: PMC7193089
doi:
Types de publication
Journal Article
Langues
eng
Pagination
494Informations de copyright
Copyright © 2020 Bergmann, Delbridge, Gempt, Feuchtinger, Walch, Schirmer, Bunk, Aschenbrenner, Liesche-Starnecker and Schlegel.
Références
Mol Cancer Res. 2009 Apr;7(4):489-97
pubmed: 19372578
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Brain Res. 2004 Jul 23;1015(1-2):169-74
pubmed: 15223381
Brain Pathol. 2011 Mar;21(2):119-29
pubmed: 21054626
Biochim Biophys Acta Rev Cancer. 2017 Apr;1867(2):95-100
pubmed: 28069394
Cancer Res. 2014 Jul 1;74(13):3579-90
pubmed: 24812274
Biochim Biophys Acta. 2009 Apr;1795(2):162-72
pubmed: 19344680
Proc Natl Acad Sci U S A. 2013 May 21;110(21):8644-9
pubmed: 23650391
Cancer Med. 2018 Oct;7(10):5281-5290
pubmed: 30175510
J Natl Cancer Inst. 2001 Sep 5;93(17):1337-43
pubmed: 11535709
Cancer Cell. 2006 Mar;9(3):157-73
pubmed: 16530701
Oncotarget. 2017 Apr 25;8(17):28074-28092
pubmed: 28427209
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neurosurgery. 2011 Oct;69(4):N21
pubmed: 21900808
Neuropathol Appl Neurobiol. 2018 Feb;44(2):139-150
pubmed: 28815663
J Neurosurg. 2015 Feb;122(2):324-30
pubmed: 25397368
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Curr Opin Cell Biol. 2015 Feb;32:121-30
pubmed: 25726916
Lab Invest. 2002 Mar;82(3):345-51
pubmed: 11896213
Neuro Oncol. 2005 Oct;7(4):465-75
pubmed: 16212811
Neuroscience. 1989;31(2):401-11
pubmed: 2797444
Int J Med Sci. 2013;10(4):399-407
pubmed: 23471193